Literature DB >> 9818932

Enhanced oxygen radical production in a transgenic mouse model of familial amyotrophic lateral sclerosis.

R Liu1, J S Althaus, B R Ellerbrock, D A Becker, M E Gurney.   

Abstract

Mutations of the SOD1 gene encoding copper/zinc superoxide dismutase (CuZnSOD) cause an inherited form of amyotrophic lateral sclerosis. When expressed in transgenic mice, the same SOD1 mutations cause progressive loss of spinal motor neurons with consequent paralysis and death. In vitro biochemical studies indicate that SOD1 mutations enhance free radical generation by the mutant enzyme. We investigated those findings in vivo by using a novel, brain-permeable spin trap, azulenyl nitrone. Reaction of azulenyl nitrone with a free radical forms a nitroxide adduct that then fragments to yield the corresponding azulenyl aldehyde. Transgenic mice expressing mutant SOD1-G93A show enhanced free radical content in spinal cord but not brain. This correlates with tissue-specific differences in the level of transgene expression. In spinal cord, the increase in free radical content is in direct proportion to the age-dependent increase in mutant human CuZnSOD expression. This increase precedes motor neuron degeneration. The higher level of human CuZnSOD expression seen in spinal cord compared with brain, and consequent difference in free radical generation, provides a basis for understanding the selective vulnerability of the spinal cord in this disease model.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9818932     DOI: 10.1002/ana.410440510

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  28 in total

1.  Reduction of axonal caliber does not alleviate motor neuron disease caused by mutant superoxide dismutase 1.

Authors:  M D Nguyen; R C Larivière; J P Julien
Journal:  Proc Natl Acad Sci U S A       Date:  2000-10-24       Impact factor: 11.205

Review 2.  Introduction to the minireviews series on mitochondrial matters in amyotrophic lateral sclerosis, Lou Gehrig’s disease.

Authors:  George H Sack
Journal:  J Bioenerg Biomembr       Date:  2011-12       Impact factor: 2.945

Review 3.  Neuronal death/survival signaling pathways in cerebral ischemia.

Authors:  Taku Sugawara; Miki Fujimura; Nobuo Noshita; Gyung Whan Kim; Atsushi Saito; Takeshi Hayashi; Purnima Narasimhan; Carolina M Maier; Pak H Chan
Journal:  NeuroRx       Date:  2004-01

4.  Marked synergism between mutant SOD1 and glutamate transport inhibition in the induction of motor neuronal degeneration in spinal cord slice cultures.

Authors:  Hong Z Yin; John H Weiss
Journal:  Brain Res       Date:  2012-02-09       Impact factor: 3.252

Review 5.  Treatment of amyotrophic lateral sclerosis--what is the next step?

Authors:  A C Ludolph
Journal:  J Neurol       Date:  2000-12       Impact factor: 4.849

Review 6.  Antioxidant gene therapy against neuronal cell death.

Authors:  Juliana Navarro-Yepes; Laura Zavala-Flores; Annadurai Anandhan; Fang Wang; Maciej Skotak; Namas Chandra; Ming Li; Aglaia Pappa; Daniel Martinez-Fong; Luz Maria Del Razo; Betzabet Quintanilla-Vega; Rodrigo Franco
Journal:  Pharmacol Ther       Date:  2013-12-12       Impact factor: 12.310

Review 7.  Mitochondrial DNA damage and reactive oxygen species in neurodegenerative disease.

Authors:  Nadee Nissanka; Carlos T Moraes
Journal:  FEBS Lett       Date:  2018-01-09       Impact factor: 4.124

Review 8.  The perplexing role of copper-zinc superoxide dismutase in amyotrophic lateral sclerosis (Lou Gehrig's disease).

Authors:  Soshanna Zittin Potter; Joan Selverstone Valentine
Journal:  J Biol Inorg Chem       Date:  2003-03-19       Impact factor: 3.358

Review 9.  Mutant CuZn superoxide dismutase in motor neuron disease.

Authors:  M E Gurney; R Liu; J S Althaus; E D Hall; D A Becker
Journal:  J Inherit Metab Dis       Date:  1998-08       Impact factor: 4.982

10.  Experimental models for the study of neurodegeneration in amyotrophic lateral sclerosis.

Authors:  Luis B Tovar-Y-Romo; Luz Diana Santa-Cruz; Ricardo Tapia
Journal:  Mol Neurodegener       Date:  2009-07-20       Impact factor: 14.195

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.